SCM
ARQT icon

Sterling Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Sterling Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.5K Sell
402
-311
-44% -$7.25K ﹤0.01% 2192
2026
Q1 		$16.8K Sell
713
-5
-0.7% -$128 ﹤0.01% 2103
2025
Q4 		$20.9K Buy
718
+459
+177% +$11.8K ﹤0.01% 2205
2025
Q3 		$4.88K Sell
259
-3
-1% -$47 ﹤0.01% 2766
2025
Q2 		$3.67K Buy
262
+146
+126% +$2.05K ﹤0.01% 2679
2025
Q1 		$1.81K Buy
116
+8
+7% +$113 ﹤0.01% 2629
2024
Q4 		$1.5K Hold
108
– – ﹤0.01% 2851
2024
Q3 		$1K Buy
+108
New +$1.07K ﹤0.01% 2527

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Sterling Capital Management's ARQT Position: Q2 2026 in Review

Sterling Capital Management reduced its Arcutis Biotherapeutics (ARQT) stake by 44% in Q2 2026, selling an estimated $7.25K and leaving 402 shares worth $10.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2192.

Sterling Capital Management first reported a position in ARQT in Q3 2024 and has held it in 8 quarters since. The position peaked at $20.9K in Q4 2025. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Sterling Capital Management held 402 shares of Arcutis Biotherapeutics worth $10.5K as of Q2 2026.
  • Sterling Capital Management sold 311 Arcutis Biotherapeutics shares in Q2 2026, an estimated $7.25K.
  • Arcutis Biotherapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2192 holding.
  • Sterling Capital Management first reported a position in Arcutis Biotherapeutics in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Arcutis Biotherapeutics position peaked at $20.9K in Q4 2025.
  • 273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.